CervoMed Inc. (CRVO)
NASDAQ: CRVO
· Real-Time Price · USD
6.24
-0.87 (-12.17%)
At close: Jun 27, 2025, 3:59 PM
6.15
-1.44%
After-hours: Jun 27, 2025, 05:48 PM EDT
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.
It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.
The company is based in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| IPO Date | May 23, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John J. Alam |
Contact Details
Address: 20 Park Plaza Boston, Massachusetts United States | |
| Website | https://www.cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President & Director |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Chief Operating Officer & Director |
| William Robert Elder J.D. | Chief Financial Officer, General Counsel & Corporate Secretary |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
| Dr. Mark A. De Rosch Ph.D. | Executive Vice President of Regulatory, Government Affairs & Program Management |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder & Director |
| Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | 8-K | Current Report |
| Jun 25, 2025 | 4 | Filing |
| Jun 25, 2025 | 4 | Filing |
| Jun 25, 2025 | 4 | Filing |
| Jun 25, 2025 | 4 | Filing |
| Jun 25, 2025 | 4 | Filing |
| Jun 25, 2025 | 4 | Filing |
| Jun 25, 2025 | 4 | Filing |
| May 23, 2025 | 3 | Filing |
| May 19, 2025 | 8-K | Current Report |